Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
578 Leser
Artikel bewerten:
(2)

Royal Philips: Philips collaborates with leading institutes to bring its breakthrough spectral CT imaging into the interventional suite

November 24, 2021

  • Philips showcases world's first spectral detector angio-CT solution at RSNA 2021
  • Solution combines breakthrough spectral detector CT imaging and real-time fluoroscopy in a flexible environment where all modalities are operated through Philips Image-Guided Therapy System - Azurion with FlexArm
  • Philips' Spectral detector CT imaging in the interventional suite brings valuable additional information in minimally-invasive procedures for areas such as oncology, stroke, and trauma care

Amsterdam, the Netherlands -Royal Philipsand its Image-Guided Therapy System - Azurion with FlexArmin a single interventional suite solution, Philips aims to give interventionalists immediate table-side access to these two key imaging modalities so they can perform procedures requiring both CT and angio guidance in one room. For the development of this integrated solution Philips is closely collaborating with leading clinical institutes such as Mayo Clinic (Rochester, MN, U.S.) and Baptist Health's Miami Cardiac & Vascular Institute (Miami, FL, U.S.). It is being presented at the 2021 Radiological Society of North America Annual Meeting (Chicago, USA, November 28 - December 2).

The goal of combining the breakthrough, first of a kind Spectral CT 7500 with the Azurion platform is to provide a seamless workflow environment in which all the necessary imaging modalities - are available directly at the patient table, fully controllable from the table-side work spot. When not in use, each modality glides smoothly away from the patient table into a parking position, giving the interventional team unrestricted access to the patient. Each system can work stand-alone if required. For interventionalists, it enables seamless efficient workflows without the need to move the patient from one imaging suite to another. For patients, this means their physicians can leverage the strengths of both systems during a single procedure.

Requiring just one scan to capture all the spectral information required to differentiate and quantify different tissues, Philips' always-on spectral CT technology enables improved detection, delineation, and quantification of lesions, leading to better-informed planning for minimally-invasive procedures and more precise interventions. In oncology, spectral CT has also demonstrated a higher sensitivity in detecting malignant findings and has improved readings of incidental findings [1] [2].

"There has been a tremendous evolution in the image-guided therapy environment," said Dr. Barry T. Katzen, founder and chief medical executive of Baptist's Health's Miami Cardiac & Vascular Institute. "We are really excited about the merger and integration of these technologies in that it might allow us to look at the treatment of a number of diseases in very new and innovative ways, potentially offering new treatment opportunities and improving patient care. I am looking forward to investigating the possibilities of this promising innovation."

"With this innovation, we are taking a uniquely patient-centric approach, aimed at bringing the latest interventional imaging modalities to the patient table rather than moving the patient to the individual modalities," said Karim Boussebaa, General Manager of Image Guided Therapy Systems at Philips. "We are excited to be co-creating the future of image guided therapy with leading clinical partners by combining the best of our award-winning modalities into a single suite."

Follow @PhilipsLiveFromfor updates throughout RSNA 2021, and join Philips at RSNA 2021where the company will spotlight its latest advanced technology driving connected workflows and smart connected imaging systems.

[1] Analysis by Aarhus University Hospital Aarhus, Denmark. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[2] Analysis by University Hospital Cleveland, USA. Results from case studies are not predictive of results in other cases. Results in other cases may vary.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 610 558 116
Email: joost.maltha@philips.com

Kathy O'Reilly
Philips Global Press Office
Tel. + 1 978-221-8919
E-mailkathy.oreilly@philips.com

About Royal Philips

Royal Philips.

Attachment

  • Philips Angio CT (https://ml-eu.globenewswire.com/Resource/Download/d724ef82-73de-47ad-a8a2-81fbb6998e26)

© 2021 GlobeNewswire (Europe)
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.